Recent review articles about prostate cancer (InTextoResearch)

InTextoResearch, scientific information agency


InTextoResearch informs on the most recent articles about prostate
cancer:

A proposal on the identification, histologic reporting, and
implications of intraductal prostatic carcinoma.
Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.
Arch Pathol Lab Med. 2007 Jul;131(7):1103-9.

Broadening the clinical use of platinum drug-based chemotherapy with
new analogues. Satraplatin and picoplatin.
Kelland L.
Expert Opin Investig Drugs. 2007 Jul;16(7):1009-21.

Clinical applications of expression profiling and proteomics in
prostate cancer.
Masters JR.
Anticancer Res. 2007 May-Jun;27(3A):1273-6.

Prostate-specific antigen in the early detection of prostate cancer.
Thompson IM, Ankerst DP.
CMAJ. 2007 Jun 19;176(13):1853-8.

NMR-based metabolomics approach to target biomarkers for human
prostate cancer.
Jordan KW, Cheng LL.
Expert Rev Proteomics. 2007 Jun;4(3):389-400.

Mechanisms of disease: high-grade prostatic intraepithelial neoplasia
and other proposed preneoplastic lesions in the prostate.
Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M.
Nat Clin Pract Urol. 2007 Jun;4(6):321-32.

Molecular genetics of prostate cancer: clinical translational
opportunities.
Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan M, Bragantini
E, Pagano F, Baffa R.
J Exp Clin Cancer Res. 2007 Mar;26(1):25-37.

Chemopreventive efficacy of silymarin in skin and prostate cancer.
Deep G, Agarwal R.
Integr Cancer Ther. 2007 Jun;6(2):130-45.

Toward the definition of the mechanism of action of silymarin:
activities related to cellular protection from toxic damage induced by
chemotherapy.
Comelli MC, Mengs U, Schneider C, Prosdocimi M.
Integr Cancer Ther. 2007 Jun;6(2):120-9.

Tumor hypoxia, DNA repair and prostate cancer progression: new targets
and new therapies.
Chan N, Milosevic M, Bristow RG.
Future Oncol. 2007 Jun;3(3):329-41.

Hormonal implications in the development and treatment of prostate
cancer.
Ip C, Hall SJ.
Endocrinol Metab Clin North Am. 2007 Jun;36(2):421-34.

Prostate stem cells and cancer.
Nikitin AY, Matoso A, Roy-Burman P.
Histol Histopathol. 2007 Sep;22(9):1043-9.

Brachytherapy--an example of a urological minimally invasive robotic
procedure.
Davies BL, Harris SJ, Dibble E.
Int J Med Robot. 2004 Jun;1(1):88-96.

Prostate specific antigen recurrence after definitive therapy.
Freedland SJ, Moul JW.
J Urol. 2007 Jun;177(6):1985-91.

The if's, and's, or but's regarding bisphosphonates for prostate
cancer.
Wilt TJ, Ensrud KE.
J Natl Cancer Inst. 2007 May 16;99(10):744-5.

MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y, Cozzi PJ.
Curr Cancer Drug Targets. 2007 May;7(3):259-71.

Low Gleason score prostatic adenocarcinomas are no longer viable
entities.
Berney DM.
Histopathology. 2007 May;50(6):683-90.

Abnormal DNA methylation, epigenetics, and prostate cancer.
Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH,
Nakayama M, De Marzo AM.
Front Biosci. 2007 May 1;12:4254-66.

Genetic etiology of hereditary prostate cancer.
Langeberg WJ, Isaacs WB, Stanford JL.
Front Biosci. 2007 May 1;12:4101-10.

Molecular epidemiology of prostate cancer: hormone-related genetic
loci.
Chokkalingam AP, Stanczyk FZ, Reichardt JK, Hsing AW.
Front Biosci. 2007 May 1;12:3436-60.

Epigenetics of prostate cancer.
Li LC.
Front Biosci. 2007 May 1;12:3377-97.

Detection and characterization of circulating and disseminated
prostate cancer cells.
Morgan TM, Lange PH, Vessella RL.
Front Biosci. 2007 May 1;12:3000-9.

Should the Gleason grading system for prostate cancer be modified to
account for high-grade tertiary components? A systematic review and
meta-analysis.
Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD.
Lancet Oncol. 2007 May;8(5):411-9.



(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb@xxxxxxxx)

.

Relevant Pages

  • Re: Delayed Treatments for Prostate Cancer
    ... "Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate ... Cancer in the United States "? ... It was a retrospective review of thousands of patients in the SEER database. ... Treatment may result in morbidity. ...
    (talk.politics.medicine)
  • Re: Medical Research-Evidence
    ... "Radical Prostatectomy versus Watchful Waiting in Early Prostate ... The only issue is whether a treatment works. ... differences in cancer survival rates over very long periods of time may be ... advantage for surgery vs. watchful waiting. ...
    (talk.politics.medicine)
  • Flaxseed Stunts The Growth Of Prostate Tumors
    ... Flaxseed Stunts The Growth Of Prostate Tumors ... prostate tumor growth, according to a study led by Duke University Medical ... surgery for the treatment of prostate cancer. ...
    (sci.med.nutrition)
  • Re: Medical Research-Evidence
    ... "Radical Prostatectomy versus Watchful Waiting in Early Prostate ... The risk of death was not seen at 6 years, ... differences must be evaluated carefully even if statistically significant. ... prostate cancer. ...
    (talk.politics.medicine)
  • Re: Medical Research-Evidence
    ... "Radical Prostatectomy versus Watchful Waiting in Early Prostate ... mortality, overall mortality, and the risks of metastasis and local ... that in the face of diagnosed prostate cancer, ... crippling symptoms of metastatic disease beyond cure is of major importance. ...
    (talk.politics.medicine)
Loading